Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma (Q35051886)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

large-cell lymphoma

1 reference

based on heuristic

inferred from title

8

object named as

Tomohiro Aoki

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kiyohiko Hatake

3

object named as

Kiyohiko Hatake

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Michinori Ogura

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kensei Tobinai

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kenichi Ishizawa

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Naokuni Uike

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Toshiki Uchida

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Tatsuya Suzuki

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Takashi Watanabe

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Dai Maruyama

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Masahiro Yokoyama

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Takatoshi Takubo

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Hideaki Kagehara

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Takafumi Matsushima

14

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

1 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

105

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

840-846

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

Peripheral neuropathy induced by microtubule-stabilizing agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317919

8 July 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12435

21 January 2018

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12435

21 January 2018

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12435

21 January 2018

The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12435

21 January 2018

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24814862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24814862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/CAS.12435

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35051886&oldid=1756316266"